Lecture on personalized healthcare in a great session at the Innovation for Health 2016 conference, discussing opportunities and challenges with 800 scientists, enterpreneurs and care professionals.
Lecture on biomarkers (principles, potentials, pitfalls) for 200 pharmaceutical professionals as part of the IMI Pharma Train course organised by the European Center for Pharmaceutical Medicine
Great evening with the Rotary Oss where I got the opportunity to discuss current and future prospects in personalized healthcare with a good group of interested people.
2016 04-21 Association of Dutch Producers of Children and Diet Nutrition (VNF...Alain van Gool
Keynote lecture at the 55-year lustrum conference of the Association of Dutch Producers of Children and Diet Nutrition (VNFKD) to reflect on the use of (specialized) nutrition in personalized healthcare.
2016 08-22 Radboud Grand Round, Nijmegen, Alain van GoolAlain van Gool
Interactive lecture with a large group of healthcare professionals, scientists and patients to illustrate developments in personalized healthcare and the role of technology to support science, innovations and medical impact. (slides in English)
2016 11-01 Biomarker Agora, Copenhagen, Alain van GoolAlain van Gool
This document discusses the development and validation of clinical molecular biomarkers. It begins with an example of how the B-RAFV600E mutation in melanoma can be used for personalized medicine approaches. It then describes efforts to validate interleukin-8 (IL-8) as a biomarker for ERK pathway inhibition, which involved extensive biomarker profiling and validation studies but ultimately found the data to be irreproducible. The document emphasizes the need for improved biomarker validation practices and increased collaboration to address gaps between biomarker discovery and clinical application.
2016 09-21 symposium Opening the BBMRI genomics infrastructure in The Netherl...Alain van Gool
Keynote lecture for the BBMRI genomics community at this BBMRI symposium, outlining my perspective on personalized medicine and health, and the various activities within The Netherlands to shape the healthRI.
2016 09-12 Europe Biobanking Week, Vienna, Alain van GoolAlain van Gool
Opening keynote of the Europe Biobanking Week, outlining reasons why we should join forces in validation and development of biomarker in personalized medicinand health.
Lecture on biomarkers (principles, potentials, pitfalls) for 200 pharmaceutical professionals as part of the IMI Pharma Train course organised by the European Center for Pharmaceutical Medicine
Great evening with the Rotary Oss where I got the opportunity to discuss current and future prospects in personalized healthcare with a good group of interested people.
2016 04-21 Association of Dutch Producers of Children and Diet Nutrition (VNF...Alain van Gool
Keynote lecture at the 55-year lustrum conference of the Association of Dutch Producers of Children and Diet Nutrition (VNFKD) to reflect on the use of (specialized) nutrition in personalized healthcare.
2016 08-22 Radboud Grand Round, Nijmegen, Alain van GoolAlain van Gool
Interactive lecture with a large group of healthcare professionals, scientists and patients to illustrate developments in personalized healthcare and the role of technology to support science, innovations and medical impact. (slides in English)
2016 11-01 Biomarker Agora, Copenhagen, Alain van GoolAlain van Gool
This document discusses the development and validation of clinical molecular biomarkers. It begins with an example of how the B-RAFV600E mutation in melanoma can be used for personalized medicine approaches. It then describes efforts to validate interleukin-8 (IL-8) as a biomarker for ERK pathway inhibition, which involved extensive biomarker profiling and validation studies but ultimately found the data to be irreproducible. The document emphasizes the need for improved biomarker validation practices and increased collaboration to address gaps between biomarker discovery and clinical application.
2016 09-21 symposium Opening the BBMRI genomics infrastructure in The Netherl...Alain van Gool
Keynote lecture for the BBMRI genomics community at this BBMRI symposium, outlining my perspective on personalized medicine and health, and the various activities within The Netherlands to shape the healthRI.
2016 09-12 Europe Biobanking Week, Vienna, Alain van GoolAlain van Gool
Opening keynote of the Europe Biobanking Week, outlining reasons why we should join forces in validation and development of biomarker in personalized medicinand health.
2016 11-15 Lygature partnership meetup, Utrecht, Alain van GoolAlain van Gool
Contribution to the opening of the Joint Innovation Mile in the Beatrix building in Utrecht, home of the offices of Lygature, HealthRI, BBMRI-NL and others to follow.
2016 09-08 Copenhagen Bioscience Lecture, Alain van GoolAlain van Gool
On invitation of the Novo Nordisck Foundation, an interactive story on personalized healthcare, biomarkers and innovation in proteomics for a group of enthousiastic young scientists.
2021 03-25 11th World Clinical Biomarkers & Companion Diagnostics, Alain van ...Alain van Gool
Closing keynote of a 3-day conference on clinical biomarkers and companion diagnostics, organised by Hanson Wade, outlining the power of omics approaches in healthcare and translation of inovations to impact.
2020 08-28 SensUs Event 2020 keynote, Eindhoven, Alain van GoolAlain van Gool
Closing keynote for international students participating in the SensUs Event 2020, where they designed and created a novel sensor for drug level monitoring in epilepsy treatment. Lecture outlined innovations in biomarkers in personalized health(care).
2020 09-07 European Center Pharmaceutical Medicine course Biomarkers, Basel, ...Alain van Gool
Tutorial lecture on biomarkers for pharmaceutical industry R&D professionals, outlining status, potential and challenges of biomarkers in pharma, clinic and society.
2015 12-09 Opening Radboud Translational Medicine, Nijmegen, Alain van GoolAlain van Gool
Keynote opening lecture at the grand opening of our new cyclotron facility, embedded in Radboud Translational Medicine and part of our Radboudumc Technology Centers. See http://www.radboudtranslationalmedicine.nl/nl/ for details.
2019 06-19 Dutch association for clinical chemistry and laboratory medicine -...Alain van Gool
Sharing my views on how X-omics biomarker analyses through next gen sequencing and mass spectrometry will change the landscape of diagnostics and clinical chemistry in the near future.
2020 02-10 European Center Pharmaceutical Medicine course - biomarkers, Basel...Alain van Gool
This document discusses biomarkers and personalized healthcare. It begins with an overview of biomarkers in the pharmaceutical industry and how they are used from drug discovery through clinical trials. It then discusses biomarkers in academic research and healthcare, and how emerging digital biomarkers could enable personalized health monitoring. The presentation identifies some translational innovation gaps, and concludes with an outlook on how biomarkers and multi-omics approaches will continue to advance personalized diagnosis and therapies.
2015 07-03 Nanonext NL Alain van Gool, AmsterdamAlain van Gool
The document discusses implementing personalized healthcare through measuring biomarkers. It notes that while many biomarkers have been discovered, few are validated and applied in diagnostic tests. There is also a gap in translating biomarkers into point-of-care applications. The document advocates for open innovation networks to help validate biomarkers across multiple centers and standardize clinical applications. Ultimately, the focus of personalized healthcare should be on the patient by providing individualized follow-up based on their molecular and clinical measurements.
2018 03-01 International Conference on Perspectives in Precision Medicine, Co...Alain van Gool
This keynote lecture reviews the historical and ongoing investments in public-private partnerships related to precision medicine and the related technological infrastructures. It served as example to the Danish community how translational biomarkers in precision medicine can be organised, as basis for further collaboration between Denmark and Netherlands.
2021 06-14 EATRIS-Plus summer school, Alain van GoolAlain van Gool
Introductory lecture for the 100 participant summer school of the EATRIS-Plus project, outlining personalized medicine, biomarker and multi-omics strategies and use cases.
2018 11-26 KNAW-AcTI symposium Personalized Health, Amsterdam, Alain van GoolAlain van Gool
Lecture at a citizen discussion evening, reviewing the promises and (ethical) considerations of technology developments to support personalized health, organised by the Royal Academy of Sciences and the Netherlands Academy of Technology and Innovation.
2019 10-14 2nd Int Congress on Precision Medicine, Munich, Alain van GoolAlain van Gool
Opening lecture at the 2nd International Congress on Precision Medicine in Munich, outlining progress in omics-based biomarkers for rare diseases, biomarker innovation gaps and multi-partner initiatives to bridge those gaps to applications. Also reviewed the highlights of our recently published Handbook of Biomarkers and Precision Medicine.
2015 09-14 Precision Medicine 2015, London, Alain van GoolAlain van Gool
Outline of my view hoe personalized health(care) is more than just targeted medicines, also including personal motivation and actions towards disease prevention. It also outlines 4 key factors that should be in order for optimal personalized health(care): 1. start with patients first, 2. Accelerate translation research to application, 3. Copy best practice, 4. Spread the word.
From Bits to Bedside: Translating Big Data into Precision Medicine and Digita...Dexter Hadley
Lecture Objectives:
1) To use examples from my research to define and introduce the ideals of precision medicine and digital health. 2) To introduce how large scale population-wide analysis of data can be used to facilitate these two ideals. 3) To introduce how freely available open data can be used to facilitate these two ideals. 4) To show how mobile technology can be used to facilitate these two ideals.
ClinicalCodes.org: An online repository of clinical code lists for primary ca...David Springate
This document discusses ClinicalCodes.org, an online repository for clinical code lists used in primary care database research. It outlines issues with a lack of published code lists, such as inability to validate or replicate studies and difficulty comparing studies over time as condition definitions change. ClinicalCodes.org aims to address these issues by providing a central location for researchers to upload, download, and archive code lists. This would improve research quality and allow other researchers to build upon previous work in a standardized way. Motivations for researchers to upload their code lists include validation of their work, increased citations, and a requirement by journals and funders for transparent and accessible code lists.
Pharmacovigilance is the science of detecting, assessing, understanding, and preventing adverse effects or any drug-related problems. The goals of pharmacovigilance are to improve patient safety, assess benefits and risks of medicines, and ensure their safe use. It involves collecting reports of adverse drug reactions (ADRs) from healthcare professionals and patients and analyzing the data to identify new safety issues and risk factors. Pharmacovigilance relies on spontaneous reporting systems but also uses active surveillance methods like cohort studies and registries to monitor drug safety post-marketing. It is a shared responsibility between drug regulators, healthcare professionals, and pharmaceutical companies to help prevent drug-related harm and protect public health.
2014 09-08 Personalized healthcare, a view in the near futureAlain van Gool
1) Professor Alain van Gool has experience in academia, pharmaceutical companies, and applied research institutes focusing on personalized healthcare, biomarkers, and 'omics technologies.
2) Personalized healthcare aims to stratify patients based on multi-level diagnoses and patient preferences to select personalized therapies.
3) A key challenge is translating complex biological data into information patients can understand to make healthcare decisions. Biomarkers must be validated from discovery to diagnostic tests to realize personalized medicine.
2017 02-22 Oxford Global Biomarker Congress, Manchester, Alain van GoolAlain van Gool
Outline of various technology infrastructures (in Radboudumc, Netherlands, European) aiming at filing innovation gaps in personalized medicine and health research.
2016 11-15 Lygature partnership meetup, Utrecht, Alain van GoolAlain van Gool
Contribution to the opening of the Joint Innovation Mile in the Beatrix building in Utrecht, home of the offices of Lygature, HealthRI, BBMRI-NL and others to follow.
2016 09-08 Copenhagen Bioscience Lecture, Alain van GoolAlain van Gool
On invitation of the Novo Nordisck Foundation, an interactive story on personalized healthcare, biomarkers and innovation in proteomics for a group of enthousiastic young scientists.
2021 03-25 11th World Clinical Biomarkers & Companion Diagnostics, Alain van ...Alain van Gool
Closing keynote of a 3-day conference on clinical biomarkers and companion diagnostics, organised by Hanson Wade, outlining the power of omics approaches in healthcare and translation of inovations to impact.
2020 08-28 SensUs Event 2020 keynote, Eindhoven, Alain van GoolAlain van Gool
Closing keynote for international students participating in the SensUs Event 2020, where they designed and created a novel sensor for drug level monitoring in epilepsy treatment. Lecture outlined innovations in biomarkers in personalized health(care).
2020 09-07 European Center Pharmaceutical Medicine course Biomarkers, Basel, ...Alain van Gool
Tutorial lecture on biomarkers for pharmaceutical industry R&D professionals, outlining status, potential and challenges of biomarkers in pharma, clinic and society.
2015 12-09 Opening Radboud Translational Medicine, Nijmegen, Alain van GoolAlain van Gool
Keynote opening lecture at the grand opening of our new cyclotron facility, embedded in Radboud Translational Medicine and part of our Radboudumc Technology Centers. See http://www.radboudtranslationalmedicine.nl/nl/ for details.
2019 06-19 Dutch association for clinical chemistry and laboratory medicine -...Alain van Gool
Sharing my views on how X-omics biomarker analyses through next gen sequencing and mass spectrometry will change the landscape of diagnostics and clinical chemistry in the near future.
2020 02-10 European Center Pharmaceutical Medicine course - biomarkers, Basel...Alain van Gool
This document discusses biomarkers and personalized healthcare. It begins with an overview of biomarkers in the pharmaceutical industry and how they are used from drug discovery through clinical trials. It then discusses biomarkers in academic research and healthcare, and how emerging digital biomarkers could enable personalized health monitoring. The presentation identifies some translational innovation gaps, and concludes with an outlook on how biomarkers and multi-omics approaches will continue to advance personalized diagnosis and therapies.
2015 07-03 Nanonext NL Alain van Gool, AmsterdamAlain van Gool
The document discusses implementing personalized healthcare through measuring biomarkers. It notes that while many biomarkers have been discovered, few are validated and applied in diagnostic tests. There is also a gap in translating biomarkers into point-of-care applications. The document advocates for open innovation networks to help validate biomarkers across multiple centers and standardize clinical applications. Ultimately, the focus of personalized healthcare should be on the patient by providing individualized follow-up based on their molecular and clinical measurements.
2018 03-01 International Conference on Perspectives in Precision Medicine, Co...Alain van Gool
This keynote lecture reviews the historical and ongoing investments in public-private partnerships related to precision medicine and the related technological infrastructures. It served as example to the Danish community how translational biomarkers in precision medicine can be organised, as basis for further collaboration between Denmark and Netherlands.
2021 06-14 EATRIS-Plus summer school, Alain van GoolAlain van Gool
Introductory lecture for the 100 participant summer school of the EATRIS-Plus project, outlining personalized medicine, biomarker and multi-omics strategies and use cases.
2018 11-26 KNAW-AcTI symposium Personalized Health, Amsterdam, Alain van GoolAlain van Gool
Lecture at a citizen discussion evening, reviewing the promises and (ethical) considerations of technology developments to support personalized health, organised by the Royal Academy of Sciences and the Netherlands Academy of Technology and Innovation.
2019 10-14 2nd Int Congress on Precision Medicine, Munich, Alain van GoolAlain van Gool
Opening lecture at the 2nd International Congress on Precision Medicine in Munich, outlining progress in omics-based biomarkers for rare diseases, biomarker innovation gaps and multi-partner initiatives to bridge those gaps to applications. Also reviewed the highlights of our recently published Handbook of Biomarkers and Precision Medicine.
2015 09-14 Precision Medicine 2015, London, Alain van GoolAlain van Gool
Outline of my view hoe personalized health(care) is more than just targeted medicines, also including personal motivation and actions towards disease prevention. It also outlines 4 key factors that should be in order for optimal personalized health(care): 1. start with patients first, 2. Accelerate translation research to application, 3. Copy best practice, 4. Spread the word.
From Bits to Bedside: Translating Big Data into Precision Medicine and Digita...Dexter Hadley
Lecture Objectives:
1) To use examples from my research to define and introduce the ideals of precision medicine and digital health. 2) To introduce how large scale population-wide analysis of data can be used to facilitate these two ideals. 3) To introduce how freely available open data can be used to facilitate these two ideals. 4) To show how mobile technology can be used to facilitate these two ideals.
ClinicalCodes.org: An online repository of clinical code lists for primary ca...David Springate
This document discusses ClinicalCodes.org, an online repository for clinical code lists used in primary care database research. It outlines issues with a lack of published code lists, such as inability to validate or replicate studies and difficulty comparing studies over time as condition definitions change. ClinicalCodes.org aims to address these issues by providing a central location for researchers to upload, download, and archive code lists. This would improve research quality and allow other researchers to build upon previous work in a standardized way. Motivations for researchers to upload their code lists include validation of their work, increased citations, and a requirement by journals and funders for transparent and accessible code lists.
Pharmacovigilance is the science of detecting, assessing, understanding, and preventing adverse effects or any drug-related problems. The goals of pharmacovigilance are to improve patient safety, assess benefits and risks of medicines, and ensure their safe use. It involves collecting reports of adverse drug reactions (ADRs) from healthcare professionals and patients and analyzing the data to identify new safety issues and risk factors. Pharmacovigilance relies on spontaneous reporting systems but also uses active surveillance methods like cohort studies and registries to monitor drug safety post-marketing. It is a shared responsibility between drug regulators, healthcare professionals, and pharmaceutical companies to help prevent drug-related harm and protect public health.
2014 09-08 Personalized healthcare, a view in the near futureAlain van Gool
1) Professor Alain van Gool has experience in academia, pharmaceutical companies, and applied research institutes focusing on personalized healthcare, biomarkers, and 'omics technologies.
2) Personalized healthcare aims to stratify patients based on multi-level diagnoses and patient preferences to select personalized therapies.
3) A key challenge is translating complex biological data into information patients can understand to make healthcare decisions. Biomarkers must be validated from discovery to diagnostic tests to realize personalized medicine.
2017 02-22 Oxford Global Biomarker Congress, Manchester, Alain van GoolAlain van Gool
Outline of various technology infrastructures (in Radboudumc, Netherlands, European) aiming at filing innovation gaps in personalized medicine and health research.
2017 03-07 World Economic Forum - Dutch topsector Life Science Health, The Ha...Alain van Gool
The document discusses the Netherlands' approach to personalized medicine and health research. It outlines key principles of precision medicine including targeting the right drug, dose, and time for each patient. It also describes the Netherlands' national infrastructure supporting personalized medicine research through biobanks, clinical records, and other data sources. Mass spectrometry is highlighted as a technique enabling discovery of new glycoprotein biomarkers from human plasma samples.
This document outlines Randy T. Nobleza's curriculum for 2014-2015 and 2015-2016 focusing on info shops as archival/curatorial projects and their sustainability. It describes various events, projects, and activities involving info shops, autonomous spaces, conferences and reading groups in the Philippines and Asia exploring political economy, knowledge practices, and transitions in the region.
Ryan Eagle founded Eagle Web Assets Inc. in 2004 after several websites hit massive success, harnessing nearly a million unique visitors a day. From the instant success of these websites, the business model was reproduced and scaled into an empire of over 450 niche websites.http://www.eaglewebassets.com/ryan-eagle.php
DEVNET-1112 The DevNet Hackathon AwardsCisco DevNet
Come see the winning projects and celebrate the winners of the DevNet Hackathon that was held prior to the opening of Cisco Live and to recognize the winners of the Hackathon that Cisco sponsored at the IETF conference in March.
EU FP7 CarTarDis project overview April 2015Alain van Gool
The document describes CarTarDis, a 4-year public-private partnership with 13 partners from 8 countries and a budget of 8.0M Euros that began on October 1, 2013. The project aims to discover novel cardiovascular drug targets through a strong interdisciplinary team with expertise in cardiovascular disease biology, drug discovery, translational medicine, omics technologies, and more. CarTarDis will utilize unique human cohort data, biobanks, CVD models and samples to generate a candidate target database, review targets, validate a shortlist, and create online dossiers to share knowledge on selected targets. The goal is to prioritize 11 targets for further validation activities to identify new treatments for cardiovascular disease.
This document contains 50 spelling questions from an English spelling test. For each question, there are 4 multiple choice answers and only one correct spelling. The questions cover a variety of commonly misspelled words and test completing sentences with the correct spelling. The test covers topics like occupations, relationships, animals, locations and more. It aims to evaluate proficiency with English spelling.
Antivirus software has improved but malware continues to evolve, using techniques like hiding, disguising itself, or waiting for commands to activate. Reading antivirus logs weekly can provide insight into attacks, even if the computer seems fine. While antivirus helps, relying only on it is risky; a layered security approach including firewalls, intrusion prevention, and endpoint protection fits all budgets. Ransomware infects computers in phases, initially tricking users then encrypting files until payment is made; ignoring early warning signs like slow performance increases risk. Businesses must educate employees to promptly report anomalies to prevent data encryption across the entire network.
Consumer barriers to mobile internet adoption in AsiaTuan Anh Nguyen
This research examines why more than 2 billion people in the region can access the internet but are holding back from doing so.
This includes data from six markets in the region: China, India, Indonesia, Philippines, Thailand and Vietnam with approximately 1,000 people in each country
Deforestation is a major threat to global biodiversity. In Madagascar, the rapid deforestation of rainforests due to population growth, cattle ranching, and mining has devastated endemic wildlife, eradicating many species found nowhere else. Similarly, in Malaysia deforestation for palm oil and timber plantations, occurring at one of the highest rates globally, is destroying peatland forests and endangered species' habitats. Deforestation disrupts nutrient cycling, removes tree cover critical for many species, and causes soil erosion and genetic diversity loss, threatening biodiversity. Strong government protection and alternative economic models are needed to curb deforestation and conserve ecosystems in biodiversity hotspots.
3 ways fragmented clinical communication is compromising patient carePatientSafe Solutions
1. Patient care is delayed due to inefficient systems and workflows
2. Multi-device digital communication complicates critical context
3. Unmanaged use of personal smartphones jeopardizes PHI security
The document describes the activities of a gnome named Pronto during his visit to the Bank of Powell. Pronto got acquainted with Betty, rode in the bank's drive-up tube, and greeted customers. He then went rock climbing, worked on his hunting skills and caught pheasants for dinner. Later, Pronto relaxed in the sun, took a motorcycle ride, and entered a fish catching contest at the bank before saying farewell on his last day.
The document analyzes millions of tweets to identify the biggest mistakes in marketing and advertising, which it calls the "7 deadly sins". The sins are identified as marketing saturation, constant interruption, poor creative quality, poor targeting, deceptive claims, insensitivity and selfishness, and excessive repetition. For each sin, example tweets expressing frustration are provided, as well as recommendations for marketers to avoid the sin such as focusing on quality over quantity and avoiding disruption of the user experience.
+ Overview of MOBILE EVOLUTION AND DEVELOPMENT OF THE INTERNET.
+ MOBILE INTERNET: TRENDS AND GROWTH
+ BENEFITS OF THE MOBILE INTERNET
+ CHALLENGES OF THE MOBILE INTERNET
+ SOLUTIONS
2016 05-24 Kick-off The Danish Biomarker Network, Copenhagen, Alain van GoolAlain van Gool
Keynote lecture given at the kick-off of The Danish Biomarker Network in Copenhagen for a great audience of enthousiastic patients, biotech/pharma developers and ICT experts.
2016 03-17 Health Valley Event 2016, Alain van GoolAlain van Gool
Sharing thoughts during the session Personalized Medicine at the Health Valley Event 2016, which again was a great event with 1100+ health care innovators !
2015 06-02 Steering group 'Personalized Medicine: eligible or not'Alain van Gool
Update for the steering group of the project "Personalized Medcine: eligble or not?", aiming to define whether and how to implement pharmacogenetic screening by first line care practitioners.
Pharma-Nutrition: a pharma perspective. View how the pharmaceutical drug development model can and should be combined with the nutrition field to optimally implement personalized healthcare.
2015 10-06 Building Bridges Biomarker symposium FIMM Helsinki, Alain van GoolAlain van Gool
A unique honour and opportunity to give a 1.5 hour lecture to young biomarker scientists to introduce biomarkers and their importance in translational medicine and personalized healthcare.
2017 05-18 Radboudumc Information Management Inspiration Point, Nijmegen, Ala...Alain van Gool
The document discusses the validation of interleukin-8 (IL-8) as a biomarker for melanoma. A study was conducted using 59 melanoma tumor tissue samples and matching serum and plasma to validate that IL-8 is elevated in melanoma. However, the results were inconsistent, as IL-8 protein levels appeared sensitive to freeze-thawing of samples. The author advocates for increasing the quality rather than quantity of biomarker research through improved collaboration to ensure better data and validation.
2013-04-23 Top Institute Pharma Spring meeting, UtrechtAlain van Gool
Companion diagnostics use biomarkers as diagnostic tools to identify patients who will respond well to specific drug therapies. The presentation discusses the increasing use of companion diagnostics in oncology drug development and clinical trials. It provides examples of biomarkers used to identify patients with melanoma who will benefit from BRAF inhibitor drugs. While some biomarkers like BRAFV600E mutations are useful targets, tumor heterogeneity poses a challenge for companion diagnostics. The presentation calls for improving the pipeline for validating biomarkers and developing them into clinical diagnostic tests.
2014 07-08 Selectbio Biomarkers 2014, CambridgeAlain van Gool
The document discusses biomarkers in personalized healthcare from discovery to clinical diagnostics, providing an overview of the speaker's experience in academia, pharmaceutical industry, and applied research focusing on biomarkers and omics technologies. It also describes the Radboud University Medical Center's focus on personalized healthcare through its technology centers and biomarker research on conditions like metabolic syndrome. The discussion emphasizes how biomarkers are evolving from diagnosis to tools that enable personalized and participatory healthcare approaches.
2018 12-07 Danone-Nutricia Precision Nutrition Forum, Utrecht, Alain van GoolAlain van Gool
1. The document discusses innovations in personalized health and healthcare using various omics technologies and big data. It highlights developments in genomics, metabolomics, glycomics, and proteomics that enable personalized diagnosis and therapy.
2. Several examples are provided of how multi-omics approaches combined with whole exome sequencing can identify new disease mechanisms and biomarkers for precision medicine in genetic disorders.
3. The development of systems approaches that integrate multi-level omics data, environment, and lifestyle factors is needed to create personalized data-driven tools to monitor health and provide customized recommendations.
This document summarizes the findings of a study that assessed how aligned 25 countries' healthcare systems are with value-based healthcare (VBHC). The study evaluated countries based on 17 indicators across 4 domains: enabling context/policies, outcomes/costs measurement, integrated/patient-focused care, and outcome-based payment. Most countries are in the early stages of aligning with VBHC. While some countries like the US are making progress, fully implementing VBHC requires fundamental changes to entrenched fee-for-service models and will take time across all systems.
2013-10-10 GTC Bio Biomarker Europe Summit 2013, BerlinAlain van Gool
Using system biomarkers to combat preventable diseases
Prof. Alain van Gool discussed using a systems biology approach and biomarkers to develop personalized health management strategies. This involves continuously monitoring individuals using routine biomarkers to detect changes and "omics" data to understand the changes. Biomarker panels can provide a functional fingerprint to make personalized decisions on health and disease management interventions like nutrition, lifestyle changes, or pharmaceutical drugs. Field labs are proposed to test these concepts in real-life settings. A systems approach is needed to better understand and define diseases, leading to more mechanism-based treatments.
Alain van Gool presented on biomarkers in personalized healthcare. He discussed how personalized medicine is shifting to personalized healthcare with a systems view that considers multiple factors. Exponential technologies will transform healthcare in the coming years through digital medicine, self-diagnosis, artificial intelligence, and big data. However, gaps remain in translating biomarker discoveries into clinical applications and demonstrating added value. Open innovation is needed to accelerate biomarker development through multi-center validation studies.
2018 11-28 SAB Interreg BIC project Baltic Sea Region, Copenhagen, Alain van ...Alain van Gool
Overview of the current challenges in biomarker commercialisation, to kick off the scientific advisory board meeting with the multidisciplinary Interreg BIC project team.
2017 06-15 Ctbg Relatiedag 2017, Ede, Alain van GoolAlain van Gool
Keynote lecture for the Ctgb (Board for the Authorisation of Plant Protection Products and Biocides) conference where I was asked to sketch the parallel between precision medicine and precision agriculture for an interested audience of 400+ scientists and companies.
Similar to 2016-02-18 Innovation for Health 2016 conference, Rotterdam Alain van Gool (20)
2023-11-14 Biomarkers Europe 2023, Berlin, Alain van Gool.pdfAlain van Gool
Lecture at the Biomarkers Europe 2023 conference for an audience of pharma scientists and omics/data solution providers. I outlined several initiatives of potential interest and discussed development of our sensitive personalized clinical biomarker test for minimal residual disease monitoring in multiple myeloma.
2023-11-09 HealthRI Biobanking day_Amsterdam_Alain van Gool.pdfAlain van Gool
Examples of lessons learned in Omics-based biomarker studies from myself and colleagues in X-omics and EATRIS, for an audience of biobankers, researchers and diagnostic/clinical chemistry experts.
2023-04-20 EATRIS-Plus Summerschool, Lisbon, Alain van GoolAlain van Gool
Closing keynote lecture at the EATRIS-Plus summerschool on personalised medicine, outlining developments, opportunities, challenges and recommendations to do next in this exciting era of personalised medicine.
2022-11-23 DTL Future of data-driven life sciences, Utrecht, Alain van Gool.pdfAlain van Gool
A pitch on directions to improve experimental reproducibility, illustrated by examples of past experiences. I made the plee to move from 'Proudly invented here' to 'Proudly copyied from', to re-use each other's eperiences in successes and failures.
2022-10-12 The future of population health_Alain van Gool.pdfAlain van Gool
1) Exponential developments in omics technologies like genomics, proteomics, and metabolomics are driving more personalized approaches to healthcare.
2) Mass spectrometry methods have been developed to sensitively detect minimal residual disease in multiple myeloma patients from plasma samples, allowing for dynamic monitoring and earlier detection of relapse compared to traditional methods.
3) Large-scale multi-omics studies incorporating data from various sources can provide a more holistic view of health and disease at both the individual and population levels, supporting personalized prevention and treatment approaches.
2022-09-08 ECPM Digital Biomarkers and AI, Basel, Alain van Gool.pdfAlain van Gool
Lecture for 150 pharma professionals to outline the potentials and things-to-do with digital biomarkers, as part of a ECPM training on digitization and AI in drug development.
2022-04-14 EuroMedLab, Munich, Alain van GoolAlain van Gool
Keynote lecture at the EuroMedLab 2021 providing an audience of clinical chemists and laboratory medicine scientists with advancements of multi-omics applications in personalized healthcare, and challenges that we need to solve as translational scientists.
2021 12-10 Amalia Science Day, Nijmegen, Alain van GoolAlain van Gool
This document discusses the use of omics technologies like genomics, proteomics, and glycoproteomics in pediatric healthcare. Specifically, it describes a study that used glycoproteomics to analyze blood samples from children with febrile illness to distinguish between viral and bacterial infections. The analysis identified glycoprotein biomarkers that could accurately classify 70-80% of samples as viral or bacterial. Integrating multiple omics data through machine learning approaches may provide a more comprehensive understanding of diseases and lead to personalized diagnosis and treatment.
2019 09-23 COST CliniMARK summerschool, Spetses, Alain van GoolAlain van Gool
Opening lecture of the COST CliniMARK summer school 'Approaches for Biomarker Discovery and Validation'. Extensive introduction in biomarker approached used in pharmaceutical industry, academic research and clinical care, and society, combined with review of biomarker innovation gaps and outlook.
Lecture describing workflows and case studies from the Translational Metabolic Laboratory @Radboudumc how to translate x-omics biomarker signatures to clinical implementation. I also highlighted new developments to join forces in the Netherlands X-omics Initiative, United for Metabolic Disease and events/book launches in the next months.
2019 03-14 Health Valley Event 2019, Nijmegen, Alain van GoolAlain van Gool
Lecture on innovations in personalized healthcare using an integrated X-omics approach towards personalized diagnostics, as part of the regional ambitious TopFit program.
2019 02-21 Oxford Global 14th Biomarker Congress, Manchester, Alain van GoolAlain van Gool
1. Professor Alain van Gool presented on using clinical x-omics to drive personalized healthcare.
2. He described case studies where combining different omic approaches like genomics, metabolomics, and glycomics led to novel disease mechanisms and therapies for rare genetic diseases.
3. Van Gool advocated for increased collaboration and standardization of omic technologies to advance precision medicine and bring clinical multi-omics to higher diagnostic and therapeutic levels.
2018 12-04 CHAINS X-omics workshop lecture, Veldhoven, Alain van GoolAlain van Gool
Introducing the innovations we plan to do in the Netherlands X-omics Initative, together with other X-omics consortium members, at a dedicated X-omics workshop at the annual congres of the Netherlands Chemistry society.
2018 11-02 Healthy Brain Cohort progress meeting, Nijmegen, Alain van GoolAlain van Gool
Highlights and anecdotes from my experiences in interdisciplinary research in big data for personalized healthcare whilst working in Europe, USA and Singapore
Does Over-Masturbation Contribute to Chronic Prostatitis.pptxwalterHu5
In some case, your chronic prostatitis may be related to over-masturbation. Generally, natural medicine Diuretic and Anti-inflammatory Pill can help mee get a cure.
share - Lions, tigers, AI and health misinformation, oh my!.pptxTina Purnat
• Pitfalls and pivots needed to use AI effectively in public health
• Evidence-based strategies to address health misinformation effectively
• Building trust with communities online and offline
• Equipping health professionals to address questions, concerns and health misinformation
• Assessing risk and mitigating harm from adverse health narratives in communities, health workforce and health system
TEST BANK For Community Health Nursing A Canadian Perspective, 5th Edition by...Donc Test
TEST BANK For Community Health Nursing A Canadian Perspective, 5th Edition by Stamler, Verified Chapters 1 - 33, Complete Newest Version Community Health Nursing A Canadian Perspective, 5th Edition by Stamler, Verified Chapters 1 - 33, Complete Newest Version Community Health Nursing A Canadian Perspective, 5th Edition by Stamler Community Health Nursing A Canadian Perspective, 5th Edition TEST BANK by Stamler Test Bank For Community Health Nursing A Canadian Perspective, 5th Edition Pdf Chapters Download Test Bank For Community Health Nursing A Canadian Perspective, 5th Edition Pdf Download Stuvia Test Bank For Community Health Nursing A Canadian Perspective, 5th Edition Study Guide Test Bank For Community Health Nursing A Canadian Perspective, 5th Edition Ebook Download Stuvia Test Bank For Community Health Nursing A Canadian Perspective, 5th Edition Questions and Answers Quizlet Test Bank For Community Health Nursing A Canadian Perspective, 5th Edition Studocu Test Bank For Community Health Nursing A Canadian Perspective, 5th Edition Quizlet Test Bank For Community Health Nursing A Canadian Perspective, 5th Edition Stuvia Community Health Nursing A Canadian Perspective, 5th Edition Pdf Chapters Download Community Health Nursing A Canadian Perspective, 5th Edition Pdf Download Course Hero Community Health Nursing A Canadian Perspective, 5th Edition Answers Quizlet Community Health Nursing A Canadian Perspective, 5th Edition Ebook Download Course hero Community Health Nursing A Canadian Perspective, 5th Edition Questions and Answers Community Health Nursing A Canadian Perspective, 5th Edition Studocu Community Health Nursing A Canadian Perspective, 5th Edition Quizlet Community Health Nursing A Canadian Perspective, 5th Edition Stuvia Community Health Nursing A Canadian Perspective, 5th Edition Test Bank Pdf Chapters Download Community Health Nursing A Canadian Perspective, 5th Edition Test Bank Pdf Download Stuvia Community Health Nursing A Canadian Perspective, 5th Edition Test Bank Study Guide Questions and Answers Community Health Nursing A Canadian Perspective, 5th Edition Test Bank Ebook Download Stuvia Community Health Nursing A Canadian Perspective, 5th Edition Test Bank Questions Quizlet Community Health Nursing A Canadian Perspective, 5th Edition Test Bank Studocu Community Health Nursing A Canadian Perspective, 5th Edition Test Bank Quizlet Community Health Nursing A Canadian Perspective, 5th Edition Test Bank Stuvia
These lecture slides, by Dr Sidra Arshad, offer a quick overview of the physiological basis of a normal electrocardiogram.
Learning objectives:
1. Define an electrocardiogram (ECG) and electrocardiography
2. Describe how dipoles generated by the heart produce the waveforms of the ECG
3. Describe the components of a normal electrocardiogram of a typical bipolar lead (limb II)
4. Differentiate between intervals and segments
5. Enlist some common indications for obtaining an ECG
6. Describe the flow of current around the heart during the cardiac cycle
7. Discuss the placement and polarity of the leads of electrocardiograph
8. Describe the normal electrocardiograms recorded from the limb leads and explain the physiological basis of the different records that are obtained
9. Define mean electrical vector (axis) of the heart and give the normal range
10. Define the mean QRS vector
11. Describe the axes of leads (hexagonal reference system)
12. Comprehend the vectorial analysis of the normal ECG
13. Determine the mean electrical axis of the ventricular QRS and appreciate the mean axis deviation
14. Explain the concepts of current of injury, J point, and their significance
Study Resources:
1. Chapter 11, Guyton and Hall Textbook of Medical Physiology, 14th edition
2. Chapter 9, Human Physiology - From Cells to Systems, Lauralee Sherwood, 9th edition
3. Chapter 29, Ganong’s Review of Medical Physiology, 26th edition
4. Electrocardiogram, StatPearls - https://www.ncbi.nlm.nih.gov/books/NBK549803/
5. ECG in Medical Practice by ABM Abdullah, 4th edition
6. Chapter 3, Cardiology Explained, https://www.ncbi.nlm.nih.gov/books/NBK2214/
7. ECG Basics, http://www.nataliescasebook.com/tag/e-c-g-basics
Integrating Ayurveda into Parkinson’s Management: A Holistic ApproachAyurveda ForAll
Explore the benefits of combining Ayurveda with conventional Parkinson's treatments. Learn how a holistic approach can manage symptoms, enhance well-being, and balance body energies. Discover the steps to safely integrate Ayurvedic practices into your Parkinson’s care plan, including expert guidance on diet, herbal remedies, and lifestyle modifications.
Promoting Wellbeing - Applied Social Psychology - Psychology SuperNotesPsychoTech Services
A proprietary approach developed by bringing together the best of learning theories from Psychology, design principles from the world of visualization, and pedagogical methods from over a decade of training experience, that enables you to: Learn better, faster!
Histololgy of Female Reproductive System.pptxAyeshaZaid1
Dive into an in-depth exploration of the histological structure of female reproductive system with this comprehensive lecture. Presented by Dr. Ayesha Irfan, Assistant Professor of Anatomy, this presentation covers the Gross anatomy and functional histology of the female reproductive organs. Ideal for students, educators, and anyone interested in medical science, this lecture provides clear explanations, detailed diagrams, and valuable insights into female reproductive system. Enhance your knowledge and understanding of this essential aspect of human biology.
Here is the updated list of Top Best Ayurvedic medicine for Gas and Indigestion and those are Gas-O-Go Syp for Dyspepsia | Lavizyme Syrup for Acidity | Yumzyme Hepatoprotective Capsules etc
Cell Therapy Expansion and Challenges in Autoimmune DiseaseHealth Advances
There is increasing confidence that cell therapies will soon play a role in the treatment of autoimmune disorders, but the extent of this impact remains to be seen. Early readouts on autologous CAR-Ts in lupus are encouraging, but manufacturing and cost limitations are likely to restrict access to highly refractory patients. Allogeneic CAR-Ts have the potential to broaden access to earlier lines of treatment due to their inherent cost benefits, however they will need to demonstrate comparable or improved efficacy to established modalities.
In addition to infrastructure and capacity constraints, CAR-Ts face a very different risk-benefit dynamic in autoimmune compared to oncology, highlighting the need for tolerable therapies with low adverse event risk. CAR-NK and Treg-based therapies are also being developed in certain autoimmune disorders and may demonstrate favorable safety profiles. Several novel non-cell therapies such as bispecific antibodies, nanobodies, and RNAi drugs, may also offer future alternative competitive solutions with variable value propositions.
Widespread adoption of cell therapies will not only require strong efficacy and safety data, but also adapted pricing and access strategies. At oncology-based price points, CAR-Ts are unlikely to achieve broad market access in autoimmune disorders, with eligible patient populations that are potentially orders of magnitude greater than the number of currently addressable cancer patients. Developers have made strides towards reducing cell therapy COGS while improving manufacturing efficiency, but payors will inevitably restrict access until more sustainable pricing is achieved.
Despite these headwinds, industry leaders and investors remain confident that cell therapies are poised to address significant unmet need in patients suffering from autoimmune disorders. However, the extent of this impact on the treatment landscape remains to be seen, as the industry rapidly approaches an inflection point.
Cell Therapy Expansion and Challenges in Autoimmune Disease
2016-02-18 Innovation for Health 2016 conference, Rotterdam Alain van Gool
1. Personalized Health(care):
more than ‘just’ targeted medicines
Professor of Personalized Healthcare
Head Radboud Center for Proteomics, Glycomics
and Metabolomics
Coordinator Radboud Technology Centers
Senior Scientist Integrator Biomarkers
Prof Alain van Gool
Innovation for Health
Rotterdam, 18 Feb 2016
2. My background in personalized health(care)
8 years academia (NL, UK)
(molecular mechanisms of disease)
13 years pharma (EU, USA, Asia)
(biomarkers, Omics)
4 years med school (NL)
(personalized healthcare, Omics, biomarkers)
4 years applied research institute (NL, EU)
(biomarkers, personalized health, nutrition)
1991-1996
(PhD)
1996-1998
(post-doc)
2009-2012
(visiting prof)
1999-2007 2007-2009 2009-2011
2011-now
2011-now (prof)
2
A person / citizen / family man
(adventures in EU, USA, Asia)
Alain van Gool, Innovation for Health, 18 Feb 2016
2016 (Scientific lead DTL-Technologies)
2016 (Head Biomarker Platform)
3. 3 Alain van Gool, Innovation for Health, 18 Feb 2016
4. Source: Chakma, Journal of Young Investigators, 16, 2009
Principle of Personalized/Precision/Targeted Medicine
4
• The right drug for right patient at right dose at right time
• Molecular biomarkers as key drivers of patient selection
4 Alain van Gool, Innovation for Health, 18 Feb 2016
5. Emerging Personalized / Precision / Targeted Medicine
Good examples personalized medicine in Oncology and Neurosciences:
• Her2/neu, BRCA, BRAF, EGFR, EML4/ALK, Cyp450, etc
Emerging companion diagnostics, also linked to non-drug therapies:
• Volker: Intestinal surgery → XIAP → Cord blood
• Beery twins: Cerebral palsy → SPR → Diet 5HTP
• Wartman: Leukemia → FLT3 → Sunitinib
• Gilbert: Healthy → BRCA → Mas/Ovarectomy
• Snyder: T2Diabetes → GCKR, KCNJ11 → Diet, exercise
• Lauerman: Scotoma, leg → JAK2 → Aspirin
• Bradfield: Healthy → CDH1 → Gastrectomy
5 Alain van Gool, Innovation for Health, 18 Feb 2016
8. Moving to Personalized Health(care)
{Source: Barabási 2007 NEJM 357; 4}
• People are different
• Different risk factors
(molecule, system, environment)
• Different preferences
• Shared desire not to get ill at all !
8 Alain van Gool, Innovation for Health, 18 Feb 2016
9. 3 key aspects of personalized health(care)
‘I want to stay healthy. If not, how do I get healthy?’
1. What to measure?
2. How much can it change?
3. What should be the follow-up for me?
9 Alain van Gool, Innovation for Health, 18 Feb 2016
10. 1. What to measure?
Exponential technological developments
• Next generation sequencing
• DNA, RNA
• Risk analysis and therapy selection
• Mass spectrometry
• Proteins, metabolites
• Monitoring of disease and treatment effects
• Imaging
• Non invasive images, real time
• Spatial view of intact organs and organisms
500
1000
1500
2000
m/z
5 10 15 20 25 30 35 40 Time [min]
10 Alain van Gool, Innovation for Health, 18 Feb 2016
14. 3 key aspects of personalized health(care)
‘I want to stay healthy. If not, how do I get healthy?’
1. What to measure?
2. How much can it change?
3. What should be the follow-up for me?
14 Alain van Gool, Innovation for Health, 18 Feb 2016
15. healthy disease disease +
treatment
2. How much can it change?
Subgroups
100%
Individual
Population
15 Alain van Gool, Innovation for Health, 18 Feb 2016
16. Personalized health(care) model
Personalized
Intervention
of patients-like-me
Personal thresholds
of persons-like-me
Big
Biomarker
Data
Molecular
Non-molecular
Environment
…
HomeostasisAllostasisDisease
Time
Disease
Health
Selfmonitoring
Adapted from Jan van der Greef, TNO
Personal profile
Personalized health
Personalized medicine
{See eg Chen … Snyder, Cell 2012, 148: 1293}
16 Alain van Gool, Innovation for Health, 18 Feb 2016
17. 3 key aspects of personalized health(care)
‘I want to stay healthy. If not, how do I get healthy?’
1. What to measure?
2. How much can it change?
3. What should be the follow-up for me?
17 Alain van Gool, Innovation for Health, 18 Feb 2016
18. 3. What should be the follow-up for me?
Personal profile data
Knowledge
Understanding
Decision
Action
18 Alain van Gool, Innovation for Health, 18 Feb 2016
19. Translation is key in Personalized Healthcare !
“I’m afraid you’re
suffering from an
increased IL-1β and
an aberrant miR843
expression”
Adapted from:
?
19 Alain van Gool, Innovation for Health, 18 Feb 2016
20. Lab values Clinical
outcomes
Pain Mobility Fatigue
INTEGRATE-HTA {R van Hoorn, W Kievit, M Tummers, GJ van der Wilt}
Intervention
Participatory healthcare
Shared decision making
20 Alain van Gool, Innovation for Health, 18 Feb 2016
21. EC DG for Research and Innovation
Alain van Gool
Brussels, 11 Sept 2012
Field lab testing
Booth #15
? Effect drugs on individual driving skills
→ TNO moving base driving simulator
{Marike Hoedemaeker, Steven Erpelinck}
21 Alain van Gool, Innovation for Health, 18 Feb 2016
22. EC DG for Research and Innovation
Alain van Gool
Brussels, 11 Sept 2012
Personalized Nutrition and Health Research
Program
For a society in which
each individual can and
wants to make a
motivated and sustainable
choice for a healthy diet
and lifestyle.
(pre-competitive public-private
innovation program)
{Nard Clabbers}
Booth #15
23. However … quality of data !?!
• Extremely important for personalized healthcare model
• Lack of reproducibility of reported studies
• Bayer – 75% NOT reproducible (n = 67)
• Amgen – 89% NOT reproducible (n = 53)
• Quality of data needs to be improved in:
• Data capture
• Data stewardship (FAIR)
{Prinz, Nat Rev Drug Disc, 2011}
{Bengley, Nature, 2012}
23 Alain van Gool, Innovation for Health, 18 Feb 2016
24. Biomarker innovation gaps
Discovery Clinical
validation/confirmation
Diagnostic
test
Number of
biomarkers
Gap 1
Gap 2
Gap 3
• Too much science-focussed biomarker discovery
• Too little development to application
24 Alain van Gool, Innovation for Health, 18 Feb 2016
25. Biomarker innovation gaps
Test, interpret, advice
“Post-traumatic Test Syndrome” ?
25 Alain van Gool, Innovation for Health, 18 Feb 2016
26. Build biomarker validation pipelines
Standardisation, harmonisation,
knowledge sharing in:
1. Assay development
2. Clinical validation
NL Roadmap Molecular Diagnostics (2012) NL Grant 4.3M Eur (2014)
26 Alain van Gool, Innovation for Health, 18 Feb 2016
27. Ongoing independent biomarker activities
27
Europe
USA
{Asadullah et al, Nature Reviews Drug Discovery, Dec 2015}
27 Alain van Gool, Innovation for Health, 18 Feb 2016
28. The Good Biomarker Practice initiative
Join forces among Europe’s major academic infrastructures + industry to:
1. Establish “Good Biomarker Practice” guidelines
- on translational research, biomarker technologies, biobanking, data stewardship.
2. Efficiently execute high quality biomarker projects
- work together in clinical validation and development of probable biomarkers.
EU
28 Alain van Gool, Innovation for Health, 18 Feb 2016
29. HEALTH-RI: ENABLING PERSONALISED HEALTH RESEARCH
Agro
Biomedical
Design of
multi-
disciplinary
experiments
Information
& Insight
e-health &
quantified
self data
Model
systems
measure genotype & phenotype
e.g. genomics, transcriptomics, proteomics,
metabolomics, bioimaging, microscopy,
quantified self, lifestyle, nutritional studies
data design, analytics &
stewardship
e.g. bioinformatics, computer science,
biostatistics, computational (systems)
biology, e-science, ICT, …
Biomaterial
and data
collections
International
reference
data
Linked-(FAIR)-data backbone
for distributed analytics & learning
Research
project
Health
objective
Nutrition & lifestyle
Biomedical & e-health
.nl
{See www.dtls.nl}
NL
30. Acknowledgements
Ron Wevers
Jolein Gloerich
Hans Wessels
Dirk Lefeber
Monique Scherpenzeel
Leo Kluijtmans
Lucien Engelen
Nathalie Bovy
Paul Smits
Maroeska Rovers
Bas Bloem
the Technology Centers
and many others
www.radboudumc.nl/personalizedhealthcare
www.radboudresearchfacilities.nl
www.radboudumc.nl/research/technologycenters
alain.vangool@tno.nl
alain.vangool@radboudumc.nl
www.linkedIn.com
www.slideshare.net/alainvangool
Many collaborators and funders
Jan van der Greef
Ben van Ommen
Bas Kremer
Lars Verschuren
Ivana Bobeldijk
Marjan van Erk
Carina de Jongh
Peter van Dijken
Peter Wielinga
Robert Kleemann
Suzan Wopereis
and many others
CarTarDis
30 Alain van Gool, Innovation for Health, 18 Feb 2016